Unmet Needs and Future Perspectives in Multiple Myeloma Treatment
A look at the unmet needs and future directions of multiple myeloma treatment.
Novel Agents Under Investigation for Multiple Myeloma
Oncologists highlight novel agents currently being investigated for the treatment of relapsed/refractory multiple myeloma.
JAVELIN Bladder 101: Study Design and Patient Outcomes
Thomas Powles, MBBS, MRCP, MD, discusses recent data from the JAVELIN Bladder 100 trial on maintenance avelumab therapy plus best supportive care versus BSC alone.
The Role of Biomarkers in Immunotherapy Selection for mUC
Experts discuss the role of biomarkers in treatment selection for patients with metastatic UC.
Unmet Needs in the Front-Line Setting for Renal Cell Carcinoma
A look at the current unmet needs in front-line renal cell carcinoma treatment.
Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma
Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.
The Role of Prophylaxis Regimens for GVHD
Yi-Bin Chen, MD, reviews factors affecting treatment selection among available pharmacological and ex vivo prophylaxis approaches for GVHD.
Counseling Patients on the Long-Term Management of GVHD
Thought leaders in stem cell transplant and cellular immunotherapy share insights into how they counsel patients about the challenges associated with the long-term management of chronic GVHD.
Susan F. Slovin, MD, PhD, Reviews Future Landscape of Systemic Therapies for Prostate Cancer
Susan F. Slovin, MD, PhD, spoke about how new approaches can support clinical practice guidelines and physician intuition in treating patients with prostate cancer.
Catherin Watson, MD, Talks Genetic Education in Ovarian Cancer
At SGO 2022, Catherine Watson, MD, spoke about how to improve genetic education for patients with ovarian cancer.
Safety and Efficacy Data: The JAVELIN Renal 101 Trial
Chung-Han Lee, MD, PhD, discusses data from the JAVELIN Renal 101 trial of axitinib/avelumab versus sunitinib in metastatic RCC.
Safety and Efficacy Data: The CheckMate 214 Trial
Mehmet Asim Bilen, MD, summarizes data from the CheckMate 214 trial on the safety and efficacy of ipilimumab/nivolumab versus sunitinib.
Facing Unmet Needs and Ongoing Trials in RR-DTC
Lori Wirth, MD, discusses the unmet needs and ongoing trials in development for patients with RR-DTC.
Patient Scenario 2: Selecting Therapy for mHSPC
Switching to a patient scenario of metastatic hormone-sensitive prostate cancer, experts discuss which therapeutic approach they would undertake.
PSMA-Targeted Therapy for nmCRPC
A brief discussion on the role of PSMA-targeted therapy’s role in managing patients with nonmetastatic castration-resistant prostate cancer.
Scott T. Tagawa, MD, Talks Current Initiatives in Prostate Cancer
Scott T. Tagawa, MD, spoke about potential approvals in the coming year for prostate cancer.
Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma
Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
Dosing Lenvatinib for First-Line Renal Cell Carcinoma Treatment
An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.
Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib
Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.
Risk Factors in the Management of Advanced Renal Cell Carcinoma
Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "JAVELIN Bladder 101: Study Design and Patient Outcomes")
